Clinical Application of New Advances in the Treatment of Head and Neck Cancer

Download All
Review the latest data and expert guidance on managing patients with head and neck cancer. This comprehensive program features clinical commentaries, short-form video learning episodes, updates to the online Interactive Decision Support Tool, and downloadable slides.
Barbara Burtness, MD
Program Director
Aarti Bhatia, MD, MPH
Barbara Burtness, MD
Elisabeth King, RN, FNP, AGN, AOCNP
Cristina P. Rodriguez, MD
Dan P. Zandberg, MD
Robert L. Ferris, MD, PhD
person default
Ranee Mehra, MD
Cristina P. Rodriguez, MD
Jared Weiss, MD

Text Modules

In response to the COVID-19 pandemic, my institution has implemented multiple procedures to protect patients and personnel from COVID-19 infection and avoid interruptions in cancer therapy.

Cristina P. Rodriguez, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: July 15, 2020 Expired: July 14, 2021

Immunotherapies have revolutionized the treatment of metastatic recurrent head and neck cancer. In this commentary, I revisit the data behind current best practice and look ahead to new combination therapies.

Barbara Burtness, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: October 8, 2020 Expired: October 7, 2021

Read my commentary to see my approach to patients with head and neck cancer and an NTRK gene fusion.

Aarti Bhatia, MD, MPH Physicians: maximum of 0.5 AMA PRA Category 1 Credits Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: November 11, 2020 Expired: November 10, 2021

Read my commentary to see my approach to managing immunotherapy-related adverse events in patients with head and neck cancer.

Elisabeth King, RN, FNP, AGN, AOCNP Physicians: maximum of 0.5 AMA PRA Category 1 Credits Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: February 12, 2021 Expired: February 11, 2022

Downloadable Slidesets

Download these slides for quick highlights on treating patients with head and neck cancer with the latest biomarker-driven therapies.

Aarti Bhatia, MD, MPH Barbara Burtness, MD Elisabeth King, RN, FNP, AGN, AOCNP Dan P. Zandberg, MD Released: April 9, 2021

Downloadable slides based on an expert video reviewing the current standard of care for your patients with advanced metastatic head and neck cancer.

Barbara Burtness, MD Released: November 11, 2020

Downloadable slides review the optimal use of immune checkpoint inhibitors in the frontline setting in patients with advanced metastatic head and neck cancer.

Barbara Burtness, MD Released: November 10, 2020

Downloadable slides review current clinical trials with immunotherapies for patients with advanced metastatic head and neck cancer.

Barbara Burtness, MD Released: January 5, 2021

Downloadable slides to review the rationale for treating NTRK fusions in patients with head and neck cancer.

Aarti Bhatia, MD, MPH Released: December 21, 2020

Download these slides to review how and when to test for NTRK fusions in patients with head and neck cancer.

Aarti Bhatia, MD, MPH Released: January 5, 2021

Download these slides to review the use of NTRK inhibitors in patients with head and neck cancer.

Aarti Bhatia, MD, MPH Released: December 22, 2020

Download these slides for quick highlights of recommended management strategies for patients with head and neck cancer experiencing immune-related adverse events.

Elisabeth King, RN, FNP, AGN, AOCNP Released: March 9, 2021

Download these slides for quick highlights on the importance of molecular testing for patients with head and neck cancer.

Elisabeth King, RN, FNP, AGN, AOCNP Released: March 18, 2021

Download these slides for quick highlights on the role of the immune system and immune escape in patients with head and neck cancer.

Dan P. Zandberg, MD Released: March 22, 2021

Download these slides for quick highlights on immunotherapy biomarkers in patients with head and neck cancer.

Dan P. Zandberg, MD Released: March 22, 2021

Interactive Decision Support Tool

Quickly access expert treatment recommendations for patients with advanced head and neck cancer with this decision tool.

Barbara Burtness, MD
Program Director
Robert L. Ferris, MD, PhD person default Ranee Mehra, MD Cristina P. Rodriguez, MD Jared Weiss, MD
Released: April 6, 2021

Video Modules

Watch this brief expert video to review the current standard of care for your patients with advanced metastatic head and neck cancer.

Barbara Burtness, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: November 11, 2020 Expired: November 10, 2021

Watch this brief expert video to review the optimal use of immune checkpoint inhibitors in the frontline setting in patients with advanced metastatic head and neck cancer.

Barbara Burtness, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: November 10, 2020 Expired: November 9, 2021

Watch this brief expert video to review the future potential of immune checkpoint inhibitors in patients with head and neck cancer.

Barbara Burtness, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: December 18, 2020 Expired: December 17, 2021

Watch this brief video with an expert to learn why testing for NTRK fusions in patients with head and neck cancer is recommended.

Aarti Bhatia, MD, MPH Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: December 21, 2020 Expired: December 20, 2021

Watch this brief expert video to learn recommended strategies for testing for NTRK fusions in patients with head and neck cancer.

Aarti Bhatia, MD, MPH Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: December 21, 2020 Expired: December 20, 2021

Watch this brief expert video to learn recommended treatment strategies for patients with head and neck cancer and NTRK fusions.

Aarti Bhatia, MD, MPH Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: December 22, 2020 Expired: December 21, 2021

Watch this brief expert video to learn recommended management strategies for patients with head and neck cancer experiencing immune-related adverse events.

Elisabeth King, RN, FNP, AGN, AOCNP Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: March 8, 2021 Expired: March 7, 2022

Watch this brief expert video on molecular testing for patients with head and neck cancer.

Elisabeth King, RN, FNP, AGN, AOCNP Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: March 18, 2021 Expired: March 17, 2022

Watch this brief expert video on the role of the immune system and immune escape in patients with head and neck cancer.

Dan P. Zandberg, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: March 22, 2021 Expired: March 21, 2022

Watch this brief expert video on the latest information on biomarkers for immunotherapy in patients with head and neck cancer.

Dan P. Zandberg, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: March 22, 2021 Expired: March 21, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue